

Wanbury Limited

Regd. Office: BSEL Tech Park, B-wing

10<sup>IT</sup> Floor, Sector-30 A, Opp. Vashi Railway Station, Vashi Navi Mumbai 400 703 Maharashtra, INDIA

Tel.: +91-22-6794 2222 +91-22-7196 3222 CIN L51900MH1988PLC048455 Email: info@wanbury.com Website: www.wanbury.com

September 9, 2024

To,
Department of Corporate Services,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051.
Scrip Symbol: WANBURY

To,
Department of Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.
Scrip Code: 524212

Dear Sirs,

Sub.: Press Release - Wanbury Limited received a Certificate of Suitability (CEP) for the launch of its new product, Dextromethorphan (API)

Wanbury Limited is pleased to announce that it has been awarded a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines (EDQM) for its Dextromethorphan active pharmaceutical ingredient (API), antitussive (cough) medicine.

The global formulation market for Dextromethorphan is valued at USD 2,500 million for FY24, having grown by 7% over the past year. With the CEP certification, Wanbury is well-positioned to initiate the commercial sales of this product in European markets.

Thanking you,

Yours truly, For Wanbury Limited

WBURY CTD.

Jitendra J. Gandhi Company Secretary